| Index | Value | Change Net / % |
|---|
| Data as of Jun 21, 2017 |
| Company | Last Sale* | Change Net / % | Share Volume |
|---|---|---|---|
| $140.74 | 1.38 ▲ 0.99% | 32,852,348 | |
![]() |
$32.01 | 1.18 ▲ 3.83% | 29,868,755 |
![]() |
$34.58 | 0.28 ▼ 0.80% | 25,211,862 |
|
|
$5.24 | 0.06 ▲ 1.16% | 20,486,948 |
|
|
$145.87 | 0.86 ▲ 0.59% | 19,920,234 |
| Company | Last Sale* | Change Net / % | Share Volume |
|---|---|---|---|
| $4.43 | 0.91 ▲ 25.85% | 394,646 | |
|
|
$2.36 | 0.45 ▲ 23.56% | 3,367,792 |
| $9.55 | 1.55 ▲ 19.38% | 494,813 | |
|
|
$41.02 | 6.61 ▲ 19.21% | 1,612,191 |
| $5.93 | 0.80 ▲ 15.59% | 26,152 |
| Company | Last Sale* | Change Net / % | Share Volume |
|---|---|---|---|
![]() |
$5.31 | 0.74 ▼ 12.23% | 15,643 |
| $12.98 | 1.65 ▼ 11.28% | 116,850 | |
|
|
$16.30 | 1.58 ▼ 8.84% | 4,000,897 |
| $7.30 | 0.70 ▼ 8.75% | 1,332,526 | |
| $22.06 | 2.05 ▼ 8.50% | 292,285 |
| Company | Last Sale* | Change Net / % | Share Volume |
|---|---|---|---|
| $140.74 | 1.38 ▲ 0.99% | 34,475,779 | |
|
|
$145.87 | 0.86 ▲ 0.59% | 21,200,397 |
|
|
$1,002.23 | 9.64 ▲ 0.97% | 2,912,651 |
|
|
$159.47 | 2.38 ▲ 1.52% | 16,985,585 |
| $13.98 | 1.34 ▲ 10.60% | 187,665,865 |
| Company | Last Sale | Price Change Net / % | Share Volume | Volume % Change |
|---|---|---|---|---|
| $32 | 5.80 ▲ 22.14% | 3,875,689 | 881% | |
|
|
$58.04 | 2.93 ▲ 5.32% | 5,905,747 | 755% |
| $33.45 | 4.15 ▲ 14.16% | 3,380,800 | 585% | |
![]() |
$35.80 | 4.22 ▲ 13.36% | 15,609,512 | 482% |
| $98.58 | 8.62 ▲ 9.58% | 8,690,285 | 416% |
| Name | Price Range |
|---|---|
| AKCEA THERAPEUTICS, IN | $12.00 - $14.00 |
| TINTRI, INC. | $10.50 - $12.50 |
| AILERON THERAPEUTICS I | $15.00 - $17.00 |
Visit Earnings Calendar for the week starting 06/18; 31 reports are scheduled.
See after hour quote for others SCS
| Company | Last Sale* | Change Net / % |
|---|---|---|
| ORCL | $46.33 | 0.49 ▲ 1.07% |
|
CLOSEX
|
|
CLOSEX
Please disable your ad blocker (or update your settings to ensure that javascript and cookies are enabled), so that we can continue to provide you with the first-rate market news and data you've come to expect from us.
CLOSEX
|